The PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genesall critical to how your body responds to semaglutide therapy
Your doctor will help you determine the best option based on your specific health needs
Clinician review timelines vary, creating pauses that are not tied to errors or missing information
is worth reading
Half-life can vary modestly between individuals depending on kidney and liver function and other factors, since these organs handle how the body processes and removes the drug
In glycemic control trials in adults with type 2 diabetes mellitus (monotherapy and combination therapy) [see Clinical Studies (14.2, 14.3)], during a treatment period ranging from 24 to 104 weeks, 64/3,907 (1.6%) of TRULICITY-treated patients developed anti-dulaglutide antibodies (referred to as anti-drug-antibodies (ADA))